Aradigm has announced that the United States Patent and Trademark Office has issued an additional patent covering several formulations of ciprofloxacin, including the company’s lead product, Pulmaquin dual release ciprofloxacin for inhalation. The patent (US Patent No. 8,119,156) will provide exclusivity for Pulmaquin until October 22, 2028. The company, which received another patent for its ciprofloxacin formulations in December 2011, is developing Pulmaquin for the treatment of bronchiectasis.
Aradigm President and CEO Igor Gonda commented, “The issuance of this composition of matter patent covering combination formulations of encapsulated and unencapsulated ciprofloxacin significantly strengthens the intellectual property estate around Pulmaquin and represents a valuable asset for Aradigm.”
“Pulmaquin has the potential to become an important treatment for bronchiectasis and cystic fibrosis patients with Pseudomonas lung infections, and other patients with lung infections. Pulmaquin has been tested extensively in preclinical tests as well as in the ORBIT-2 Phase 2b bronchiectasis study in which we found outstanding antimicrobial activity coupled with good safety and tolerability and, most importantly, a positive impact on prevention of pulmonary exacerbations compared to placebo. We look forward to moving to Phase 3 with a strategic partner as soon as possible.”
The company says that it is filing for patents in additional territories.
Read the Aradigm press release.
